Zilebesiran, a ribonucleic acid interference agent targeting angiotensinogen, proves a promising approach in hypertension
Author:
- 1 July 2024
- journal article
- editorial
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (10) , e41-e43
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- RNA Interference With Zilebesiran for Mild to Moderate HypertensionJAMA, 2024
- Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertensionExpert Review of Clinical Pharmacology, 2023
- Zilebesiran, an RNA Interference Therapeutic Agent for HypertensionNew England Journal of Medicine, 2023
- Small interfering RNA: Discovery, pharmacology and clinical development—An introductory reviewBritish Journal of Pharmacology, 2022
- Conventional Vasopressor and Vasopressor‐Sparing Strategies to Counteract the Blood Pressure–Lowering Effect of Small Interfering RNA Targeting AngiotensinogenJournal of the American Heart Association, 2022
- Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participantsThe Lancet, 2021
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolNew England Journal of Medicine, 2020
- Adherence in HypertensionCirculation Research, 2019
- Reversal of siRNA-mediated gene silencing in vivoNature Biotechnology, 2018
- Combined Angiotensin Inhibition for the Treatment of Diabetic NephropathyNew England Journal of Medicine, 2013